Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors with functions in the vascular wall

Zeitschrift fur Kardiologie

Volumn 90, Issue SUPPL. 3, 2001, Pages 125-132

  Chinetti, G ^a   Fruchart, J C ^a   Staels, B ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Endothelial cell; Gene expression; Macrophage; Smooth muscle cell; Transcription factors

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; CELL NUCLEUS RECEPTOR; FATTY ACID DERIVATIVE; FIBRIC ACID DERIVATIVE; IBUPROFEN; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INTERLEUKIN 2; INTERLEUKIN 6; LEUKOTRIENE B4; METALLOPROTEINASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; ENDOTHELIUM CELL; HUMAN; LIPID METABOLISM; MACROPHAGE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY MECHANISM; SMOOTH MUSCLE FIBER; T LYMPHOCYTE;

ANIMALS; ARTERIOSCLEROSIS; CALCINOSIS; ENDOTHELIUM, VASCULAR; HUMANS; MACROPHAGES; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0035067770     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (84)

1. The nuclear receptor superfamily: The second decade
2. Differential expression of peroxisome proliferator-activated receptors: Tissue distribution of PPARα, β and γ in the adult rat
3. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor α in humans
4. Member of peroxisome proliferator-activated receptor family of transcription factors is differentially expressed by oligodendrocytes
5. Differential expression of peroxisome proliferator-activated receptor-α, -β and -γ during rat embryonic development
6. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation
7. Polarity and specificity sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element
8. Fibrates increase human Rev-erbα expression in liver via a novel peroxisome proliferator-activated receptor response element
9. Activation of peroxisome proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages
10. Cloning and identification of mouse steroid receptor co-activator-1 (mSRC-1), as a co-activator of peroxisome proliferator-activated receptor γ
11. Isolation and characterisation of PBP, a protein that interacts with peroxisome proliferator-activated receptor
12. Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand-independent trans-activating domain
13. The peroxisome proliferator-activated receptor alpha is a phosphoprotein: Regulation by insulin
14. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site
15. Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase
16. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
17. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
18. Cross-talk between Janus Kinase-Signal Transducer Activator of Transcription (JAK-STAT) and peroxisome proliferator-activated receptor α (PPARα) signaling pathways
19. PPAR activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells
20. Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of PPARα activators
21. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells
22. PPAR activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the AP-1 signaling pathway
23. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
24. mPPARγ2: Tissue-specific regulator of an adipocyte enhancer
25. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa
26. Expression of peroxisome proliferator-activated receptor α (PPARα) in primary cultures of human vascular endothelial cells
27. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-I expression
28. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo
29. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells
30. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL
31. Macrophages in human atheroma contain PPARgamma: Differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPAR-gamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro
32. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
33. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors
34. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ
35. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ
36. The PPARα-leukotriene B4 pathway to inflammation control
37. 15-Deoxy-Δ12,14 prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
38. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation
39. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ
40. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15 lipoxygenase
41. Oxidized phospholipids activate PPARα in a phospholipase A2-dependent manner
42. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ)
43. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
44. Atherosclerosis - An inflammatory disease
45. Mechanism of action of fibrates on lipid and lipoprotein metabolism
46. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol
47. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
48. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
49. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
50. Antiatheromatous effects of fenofibrate, are independent of its hypolipidemic effect in cholesterol-fed rabbits
51. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
52. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
53. Activation of PPARα or γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells
54. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-γ and nuclear factor-κB
55. Suppression of rat thromboxane synthase gene transcription by peroxisome proliferator-activated receptor γ in macrophages via an interaction with NRF2
56. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
57. Inhibition of IkappaB kinase phosphorylation by 15-deoxy-Delta (12,14)-prostaglandin J (2) in activated murine macrophages
58. 12,14-prostaglandin J2
59. Inhibition of inducible nitric oxyde synthase by peroxisome proliferator-activated receptor agonists: Correlation with induction of heme oxygenase 1
60. Oxidized LDL reduces monocytre CCR2 expression through pathways involving peroxisome proliferator-activated γ
61. Isolation of the human peroxisome proliferator-activated receptor γ cDNA: Expression in hematopoietic cells and chromosomal mapping
62. The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses
63. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists. PPARgamma co-association with transcription factor NFAT
64. Thiazolidinediones inhibit the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells
65. Role of peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells
66. Peroxisome proliferator-activated receptor-γ activators inhibit IFN-γ-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells
67. Thiazolidinedione inhibits production of RANTES in a cytokine-treated human lung epithelial cell line
68. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction
69. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators
70. 2
71. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: A new possible role of PPARgamma on vascular endothelial function
72. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function
73. Insulin resistance and thrombosis: A cardiologist's view
74. Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells
75. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes: Role of the peroxisome proliferator-activated receptor alpha
76. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia
77. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients
78. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation
79. Effects of pioglitazone on calcium channels in vascular smooth muscle cells
80. 2+ currents and not endothelial nitric oxide production
81. Troglitazone upregulates nitric oxyde synthesis in vascular smooth muscle cells
82. 2 gene in vascular smooth muscle cells by a nuclear factor kappaB and peroxisome proliferator-activated receptor-mediated process
83. Secretory phospholipase A2 and lipoprotein lipase enhance 15-lipoxygenase-induced enzymic and nonenzymic lipid peroxidation in low-density lipoproteins
84. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyper-lipoproteinemia IIb